Saturday 17 October 2026
Export UPC’s income statement to Excel — free account
Universe Pharmaceuticals INC
UPC Healthcare Drug Manufacturers Specialty & Generic
Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
3.97
0.18
−4.34%
Follow UPC
Universe Pharmaceuticals INC (UPC) P/E ratio
Universe Pharmaceuticals INC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 9,177× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 2,865× | 0.00% |
| FY2021 | 2,865× | 61,417.08% |
| FY2020 | 4.7× | 0.00% |
| FY2019 | 4.7× | 0.00% |
| FY2018 | 4.7× | 0.00% |
| FY2018 | 4.7× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2023 | 0.0× | — |
| Sep 2022 | 2,865× | 0.00% |
| Mar 2022 | 2,865× | 0.00% |
| Sep 2021 | 2,865× | 72,769.43% |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9,177×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TXMD TherapeuticsMD, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| AYTU Aytu BioPharma, Inc. compare | n/m |
| BFRI Biofrontera Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | n/m |
| UPC Universe Pharmaceuticals INC | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | 0.2× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)